Pediatrix Medical Group, Inc. (MD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed financial performance: revenue increased by 5%, but operating and net income decreased due to higher costs. EBITDA remained flat, while cash flow improved. The absence of strategic discussions and the risk acknowledgment in forward-looking statements indicate uncertainty. These mixed signals suggest a neutral stock price movement over the next two weeks.
Key Financial Performance
Revenue $500 million, a 5% increase year-over-year, driven by higher patient volumes and improved payer mix.
Operating Income $50 million, a 10% decrease year-over-year, due to increased labor costs and investment in technology.
Net Income $30 million, a 15% decrease year-over-year, attributed to higher interest expenses and depreciation.
EBITDA $70 million, flat year-over-year, as cost savings offset increased expenses.
Cash Flow from Operations $40 million, a 20% increase year-over-year, due to improved collections and operational efficiencies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-Looking Statements: The company acknowledges that forward-looking statements are based on assumptions and assessments that may not materialize as expected, posing a risk to actual results, developments, and business decisions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AG Research
Administrative Officer
Bank AG
Blair LLC
CEO Executive
CFO Mardula
Chairman Kasandra
Chief Administrative
Division EDT
Division Jack
Division Pito
EDT Hello
Executive Chairman
Executive VP
General Secretary
General today
Group Conference
Hello Pediatrix
Inc Chief
Instructions conference
Jack Slevin
Jefferies LLC
Kasandra Rossi
LLC Research
Mardula Blair
Officer Executive
Ordan CEO
Pediatrix Medical
Pito Chickering
Research Division
Rossi Executive
Secretary Ordan
Slevin Jefferies
conference General
MD Transcript
Pediatrix Medical Group, Inc. (MD) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call reveals mixed financial performance: revenue increased by 5%, but operating and net income decreased due to higher costs. EBITDA remained flat, while cash flow improved. The absence of strategic discussions and the risk acknowledgment in forward-looking statements indicate uncertainty. These mixed signals suggest a neutral stock price movement over the next two weeks.
Pediatrix Medical Group, Inc. (MD) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings report presents mixed signals. While the company shows operational strengths like improved cash collections and a share buyback program, it faces challenges with declining NICU volumes and increased G&A expenses. The Q&A section reveals uncertainties in M&A contributions and flat pricing assumptions, which could dampen growth expectations. Despite positive elements like technological advancements and operational strengthening, the overall sentiment remains neutral due to these offsetting factors.
Pediatrix Medical Group, Inc. (MD) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call highlights strong adjusted EBITDA, effective cost management, and a positive cash flow. Despite a year-over-year revenue decline, same-unit growth and pricing improvements are strong. The company has also been actively repurchasing shares, which is generally positive for stock price. The Q&A revealed a focus on low debt and strategic acquisitions, though some responses lacked specificity. Overall, the financial health and strategic moves suggest a positive outlook for the stock price in the short term.
Pediatrix Medical Group, Inc. (MD) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A reveal a generally positive outlook, with a raised EBITDA outlook, strong NICU growth, and improved cash flow. While revenue decreased, same-unit revenue grew, and expenses were managed effectively. The Q&A section highlighted successful arbitration and stable margins, though management's vague responses on Medicaid expansion introduce some uncertainty. Overall, the raised guidance, strong financial performance, and strategic focus on partnerships suggest a positive stock price movement, likely within the 2% to 8% range.
MD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
